# US 2008/0269341 A1 · Method for Correcting a Lipid Imbalance in a Subject

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0269341 A1
- Document ID: US20080269341A1
- Status: Published application
- Kind: A1
- Application number: 12/097,229
- Filed: 2006-12-13
- Published: 2008-10-30
- Earliest claimed: 2005-12-13
- Assignees: The Royal Institution for the Advancement of Learning/Mcgill University
- Inventors: Danuta Radzioch; Claudine Guilbault; Juan Bautista De Sanctis
- Web page: https://patentgrep.com/patent/US20080269341A1

## CPC

- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods for the treatment of a disease or condition associated with lipid imbalance, comprising (a) decreasing arachidonic acid (AA) levels, (b) increasing docosahexaenoic acid (DHA) levels, (c) increasing DHA/AA ratio or (d) any combination of (a)-(c) in a subject using fenretinide. The invention also relates to diagnostic and screening methods based on the determination of lipid levels.

## Claims

### Claim 1

A method of (a) decreasing arachidonic acid (AA) levels, (b) increasing docosahexaenoic acid (DHA) levels, c) increasing the DHA/AA ratio, or (d) any combination of (a)-(c) in a subject, said method comprising administering to said subject fenretinide, an analog thereof or a pharmaceutically-acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein said increase or decrease is systemic.

### Claim 3 (depends on 1)

The method of claim 1 wherein said subject suffers from a disease or condition associated with a lipid imbalance.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said subject has (a) a DHA/AA ratio of 0.4 or less, (b) DHA levels of 3.5 ng/μg of phosphate or less, (c) AA levels of 40 ng/μg of phosphate or more or (d) any combination of (a) to (c), prior to said administration.

### Claim 5 (depends on 3)

The method of claim 3, wherein said subject suffers from an infectious disease.

### Claim 6 (depends on 5)

The method of claim 5, wherein said infectious disease is an opportunistic infection.

### Claim 7 (depends on 6)

The method of claim 6, wherein said opportunistic infection is a bacterial infection.

### Claim 8 (depends on 3)

The method according to claim 3, wherein said subject suffers from bone disease.

### Claim 9 (depends on 8)

The method of claim 8, wherein said bone disease is osteopenia or osteoporosis.

### Claim 10 (depends on 1)

The method of claim 1, wherein said DHA and AA are phospholipid-associated fractions of DHA and AA.

### Claim 11 (depends on 1)

The method of claim 1, wherein said subject is a mammal.

### Claim 12 (depends on 11)

The method of claim 11, wherein said mammal is a human.

### Claim 13

A method for assessing bone disease in a subject, said method comprising determining whether (a) DHA level is decreased, (b) AA level is increased, (c) DHA/AA ratio is decreased, or (d) any combination of (a) to (c), in a biological sample of said subject; relative to a corresponding control level or ratio,
wherein said increase or decrease is indicative that said subject suffers from bone disease.

### Claim 14

A method for determining whether a subject has an increased risk of developing bone disease, said method comprising determining whether (a) DHA level is decreased, (b) AA level is increased, (c) DHA/AA ratio is decreased, or (d) any combination of (a) to (c), in a biological sample of said subject; relative to a corresponding control level or ratio,
wherein said increase or decrease is indicative that said subject has an increased risk of developing bone disease.

### Claim 15 (depends on 13)

The method of claim 13, wherein said control level or ratio is selected from a corresponding level or ratio determined in a biological sample from a subject not suffering from bone disease and an established standard level or ratio.

### Claim 16 (depends on 13)

The method of claim 13, wherein said method is for prognosticating bone disease and said control level or ratio is determined in a biological sample obtained from said subject at an earlier time.

### Claim 17

A method for identifying a compound for treating or preventing bone disease, comprising determining whether (a) DHA level is decreased, (b) AA level is increased, (c) DHA/AA ratio is decreased, or (d) any combination of (a) to (c), in the presence versus the absence of a test compound,
wherein said increase or decrease is indicative that said test compound can be used for treating or preventing bone disease.

### Claim 18 (depends on 13)

The method according to claim 13, wherein said bone disease is osteopenia or osteoporosis.

### Claim 19

A method of treating a disease or condition associated with a lipid imbalance in a subject, said method comprising:
(i) assessing (a) DHA level, (b) AA level, (c) DHA/AA ratio, or (d) any combination of (a) to (c), in a biological sample obtained from said subject; and
(ii) administering fenretinide, an analog thereof or a pharmaceutically-acceptable salt thereof to said subject if said (a) DHA level is decreased, (b) AA level is increased, (c) DHA/AA ratio is decreased, or (d) any combination of (a) to (c), relative to a corresponding control level or ratio.

### Claim 20 (depends on 44)

The method of claim 44, wherein said infectious disease is an opportunistic infection.

### Claim 21 (depends on 20)

The method of claim 20, wherein said opportunistic infection is a bacterial infection.

### Claim 22 (depends on 45)

The method of claim 45, wherein said bone disease is osteopenia or osteoporosis.

### Claim 23 (depends on 19)

The method of claim 19, wherein said DHA and AA are phospholipid-associated fractions of DHA and AA.

### Claim 24 (depends on 19)

The method of claim 19, wherein said subject is a mammal.

### Claim 25 (depends on 24)

The method of claim 24, wherein said mammal is a human.

### Claim at position 26

26-39. (canceled)

### Claim 40 (depends on 8)

The method of claim 8, wherein said administration results in an increase in osteoblast formation.

### Claim 41 (depends on 14)

The method of claim 14, wherein said control level or ratio is selected from a corresponding level or ratio determined in a biological sample from a subject not suffering from bone disease and an established standard level or ratio.

### Claim 42 (depends on 14)

The method of claim 14, wherein said bone disease is osteopenia or osteoporosis.

### Claim 43 (depends on 17)

The method of claim 17, wherein said bone disease is osteopenia or osteoporosis.

### Claim 44 (depends on 19)

The method of claim 19, wherein said subject suffers from an infectious disease.

### Claim 45 (depends on 19)

The method of claim 19, wherein said subject suffers from bone disease.

### Claim 46 (depends on 45)

The method of claim 45, wherein said administration results in an increase in osteoblast formation.
